| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0002 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0003 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | -0.14 | 0.0004 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0004 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | BRD-K50799972 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0004 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.14 | 0.0005 |